Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Heart Failure
Interventions: Nebulized Sodium Nitrite, Placebo; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 40 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 11 more

Conditions: Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions: Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Advanced or Metastatic NSCLC
Interventions: Datopotamab deruxtecan, Durvalumab, Carboplatin, AZD2936, MEDI5752, AZD7789; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: La Jolla, California • Santa Ana, California • St Louis, Missouri + 7 more

Conditions: Normal Healthy
Interventions: PF-05221304, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Interventions: NGM707, NGM707 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Proliferative Vitreoretinopathy
Interventions: ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure; Drug · Other
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more

Conditions: Lung Cancer
Interventions: ZD6474, Carboplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lower Urinary Tract Symptoms, Overactive Bladder
Interventions: Urodynamics + TETRA - NIRS; Device
Lead sponsor: Laborie Medical Technologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostatic Neoplasms
Interventions: TAK-700; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 19
States / cities: Beverly Hills, California • Los Angeles, California • Aventura, Florida + 8 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: ADVM-043; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Charleston, South Carolina

Conditions: COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions: Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms; Other
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hearing Loss
Interventions: Categorical loudness scaling based fitting using the research fitting system., Behavioural fitting using Custom Sound Suite (CSS 6.3) Software; Device
Lead sponsor: Cochlear; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lone Tree, Colorado

Conditions: Myeloma
Interventions: Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: PT027, PT007; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Cervical Cancer, Hiv
Interventions: Retention in cervical cancer care intervention; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: CYP2C19 Genetic Variants
Interventions: Limonene; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Childhood Vaccinations
Interventions: Baseline Survey, Pre-intervention Survey, Morally Congruent Message, Morally Non-Congruent Message, Control Message, Post-Intervention Survey; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia
Interventions: ERAS-007, ERAS-601, Gilteritinib; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Dallas, Texas • Houston, Texas + 1 more

Conditions: Posttraumatic Stress Disorder
Interventions: imaginal therapy, exercise, self-care; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Fort Hood, Texas

Conditions: Colorectal Cancer
Interventions: Brochure regarding sedentary behavior; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Posterior Fossa Ependymal Tumor
Interventions: Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Multiple Myeloma
Interventions: Dendritic Cell Tumor Fusion; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Search by objective public record fields.

Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF

FirstStep2Health Intervention

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Phase II Study of ZD6474 in Advanced NSCLC

Tetra-NIRS Clinical Study

Safety Study of TAK-700 in Subjects With Prostate Cancer.

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Study of Default Options in Advance Directives

Comparing the Performance of a Categorical Loudness Scaling Based Fitting With a Behavioural Fitting in Adults With a Nucleus Cochlear Implant 3 Months Post-activation

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2

CYP2C19 Variants and Limonene Metabolism

Tailoring of Vaccine-Focused Messages: Moral Foundations

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

The Role of Exercise in the Treatment of PTSD Symptoms

Reducing Sedentary Behaviors Among Colorectal Cancer Survivors

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma